Correlation Between Tarsus Pharmaceuticals and Apogee Therapeutics,

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Tarsus Pharmaceuticals and Apogee Therapeutics, at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Tarsus Pharmaceuticals and Apogee Therapeutics, into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Tarsus Pharmaceuticals and Apogee Therapeutics, Common, you can compare the effects of market volatilities on Tarsus Pharmaceuticals and Apogee Therapeutics, and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Tarsus Pharmaceuticals with a short position of Apogee Therapeutics,. Check out your portfolio center. Please also check ongoing floating volatility patterns of Tarsus Pharmaceuticals and Apogee Therapeutics,.

Diversification Opportunities for Tarsus Pharmaceuticals and Apogee Therapeutics,

-0.65
  Correlation Coefficient

Excellent diversification

The 3 months correlation between Tarsus and Apogee is -0.65. Overlapping area represents the amount of risk that can be diversified away by holding Tarsus Pharmaceuticals and Apogee Therapeutics, Common in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Apogee Therapeutics, and Tarsus Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Tarsus Pharmaceuticals are associated (or correlated) with Apogee Therapeutics,. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Apogee Therapeutics, has no effect on the direction of Tarsus Pharmaceuticals i.e., Tarsus Pharmaceuticals and Apogee Therapeutics, go up and down completely randomly.

Pair Corralation between Tarsus Pharmaceuticals and Apogee Therapeutics,

Given the investment horizon of 90 days Tarsus Pharmaceuticals is expected to generate 0.68 times more return on investment than Apogee Therapeutics,. However, Tarsus Pharmaceuticals is 1.48 times less risky than Apogee Therapeutics,. It trades about 0.3 of its potential returns per unit of risk. Apogee Therapeutics, Common is currently generating about -0.07 per unit of risk. If you would invest  3,303  in Tarsus Pharmaceuticals on September 24, 2024 and sell it today you would earn a total of  2,151  from holding Tarsus Pharmaceuticals or generate 65.12% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthWeak
Accuracy100.0%
ValuesDaily Returns

Tarsus Pharmaceuticals  vs.  Apogee Therapeutics, Common

 Performance 
       Timeline  
Tarsus Pharmaceuticals 

Risk-Adjusted Performance

24 of 100

 
Weak
 
Strong
Solid
Compared to the overall equity markets, risk-adjusted returns on investments in Tarsus Pharmaceuticals are ranked lower than 24 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively unfluctuating basic indicators, Tarsus Pharmaceuticals unveiled solid returns over the last few months and may actually be approaching a breakup point.
Apogee Therapeutics, 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Apogee Therapeutics, Common has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unsteady performance in the last few months, the Stock's technical and fundamental indicators remain rather sound which may send shares a bit higher in January 2025. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders.

Tarsus Pharmaceuticals and Apogee Therapeutics, Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Tarsus Pharmaceuticals and Apogee Therapeutics,

The main advantage of trading using opposite Tarsus Pharmaceuticals and Apogee Therapeutics, positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Tarsus Pharmaceuticals position performs unexpectedly, Apogee Therapeutics, can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Apogee Therapeutics, will offset losses from the drop in Apogee Therapeutics,'s long position.
The idea behind Tarsus Pharmaceuticals and Apogee Therapeutics, Common pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .

Other Complementary Tools

Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA